Cargando…

NFB-02. TREATMENT OF PAIN AND TUMOR GROWTH IN NF2

BACKGROUND: Neurofibromatosis Type 2 (NF2) is an autosomal dominant disorder characterized by multiple nervous system tumors. Chronic pain affects the majority of patients with NF2 and is the primary factor that contributes to decreased quality of life. There are limited therapies that effectively r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hemenway, Molly, Nellan, Anan, McMahon, Kate, Foreman, Nicholas, Reddy, Kartik, Suttman, Alexandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Neurofibromatosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715678/ http://dx.doi.org/10.1093/neuonc/noaa222.606

Ejemplares similares

RARE-27. DOUBLE MUTATIONS: DIFFERENT GERMLINE AND TUMOR MUTATIONS LEAD TO POOR OUTCOMES
por: Hemenway, Molly, et al.
Publicado: (2020)

NFB-03. TRAMETINIB FOR ORBITAL PLEXIFORM NEUROFIBROMAS IN YOUNG CHILDREN WITH NF1
por: Toledano, Helen, et al.
Publicado: (2020)

NFB-11. WHITE MATTER DIFFERENCES IN CHILDREN WITH NF1 COMPARED TO CONTROLS
por: Bruckert, Lisa, et al.
Publicado: (2020)

NFB-01. FUNCTIONAL CHARACTERIZATION OF ATRX LOSS IN NF1-ASSOCIATED GLIOMA AND MPNST
por: Yuan, Ming, et al.
Publicado: (2020)

NFB-13. TRAMETINIB FOR PLEXIFORM NEUROFIBROMA AND RECURRENT LOW-GRADE GLIOMA
por: Sato, Aimee, et al.
Publicado: (2020)

NFB-18. IMMUNE FUNCTION IN CHILDREN TREATED WITH TRAMETINIB
por: Moukhaiber, Perla, et al.
Publicado: (2020)

NFB-14. PSYCHOSOCIAL OUTCOMES IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 AND PLEXIFORM NEUROFIBROMAS
por: Damodharan, Sudarshawn, et al.
Publicado: (2020)

NFB-21. Neurofibromatosis Type I in the Setting of Neuro-Oncology
por: Hemenway, Molly
Publicado: (2022)

NFB-17. MEK INHIBITOR BINIMETINIB SHOWS CLINICAL ACTIVITY IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1- ASSOCIATED PLEXIFORM NEUROFIBROMAS: A REPORT FROM PNOC AND THE NF CLINICAL TRIALS CONSORTIUM
por: Mueller, Sabine, et al.
Publicado: (2020)

NFB-06. TREATMENT CHALLENGES IN PEDIATRIC GLIOBLASTOMA MULTIFORME WITH CONCURRENT SOMATIC AND GERMLINE NF1 MUTATIONS WITH GERMLINE MISMATCH REPAIR MUTATIONS: TWO UNIQUE CASES
por: Baig, Muhammed, et al.
Publicado: (2020)

NFB-08. PHASE II STUDY OF AXITINIB IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS
por: Phadnis, Sheetal, et al.
Publicado: (2020)

NFB-09. ENROLLMENT AND CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED, NEUROFIBROMATOSIS TYPE 1 ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG): PRELIMINARY RESULTS FROM AN INTERNATIONAL MULTI-CENTER NATURAL HISTORY STUDY
por: Fisher, Michael J, et al.
Publicado: (2020)

NFB-12. TRAMETINIB THERAPY FOR PEDIATRIC PATIENTS WITH REFRACTORY LOW GRADE GLIOMA OR EXTENSIVE SYMPTOMATIC PLEXIFORM NEUROFIBROMA
por: Hounjet, Celine D, et al.
Publicado: (2020)

NFB-05. AN UNUSUAL PRESENTATION OF RECURRENT LANGERHANS CELL HISTIOCYTOSIS OF THE CRANIOFACIAL BONES IN A PATIENT WITH NEUROFIBROMATOSIS TYPE I
por: Chaffee, Blake, et al.
Publicado: (2020)

NFB-07. USE OF PEGYLATED INTERFERON α- 2b IN PEDIATRIC PATIENTS AFFECTED BY UNRESECTABLE PLEXIFORM NEUROFIBROMAS: MONOCENTRIC EXPERIENCE
por: Cacchione, Antonella, et al.
Publicado: (2020)

NFB-16. mTOROPATHIES AND SUBEPENDYMAL GIANT CELL ASTROCYTOMAS: PREDICTIVE VALUE OF GERMINAL TSC1/2 MUTATIONS SCREENING IN FAMILIAL CASES
por: Abdelmoula, Nouha Bouayed, et al.
Publicado: (2020)

NFB-04. EXAMINING DIFFUSION, ARTERIAL SPIN-LABELED PERFUSION, AND VOLUMETRIC CHANGES IN THE NEUROFIBROMATOSIS TYPE 1 BRAIN USING AN ATLAS-BASED, MULTI-PARAMETRIC APPROACH
por: Tam, Lydia, et al.
Publicado: (2020)

NFB-02. Maternal high-fat diet exposure increases the proliferation and glial differentiation of the cells of origin for NF1-optic glioma
por: Zhang, Kailong, et al.
Publicado: (2022)

NFB-17. "Optic Pathway findings in children with Neurofibromatosis type-1 (NF-1)
por: Roka, Kleoniki, et al.
Publicado: (2022)

NFB-15. "Cognitive Impairments in Children and Adolescents with Neurofibromatosis"
por: Mavrea, Kalliopi, et al.
Publicado: (2022)

NFB-12. Effect of trametinib on leg length discrepancy in a child with NF1 related plexiform neurofibroma
por: Pradeep, Celia, et al.
Publicado: (2022)

NFB-23. Extent of tumor but not location may be predictive of longitudinal disease severity in children with NF1-associated gliomas requiring treatment
por: Chaturvedi, Sneha, et al.
Publicado: (2022)

NFB-07. Meningiomatosis in an adolescent with TRAF-7 mutation related syndrome
por: Torres, Marleni, et al.
Publicado: (2022)

NFB-20. Pre-clinical models of Mismatch Repair Deficient Gliomas
por: Putnam, Ethan, et al.
Publicado: (2022)

NFB-05. A family-centered neurocutaneous syndrome clinic in the age of targeted therapies
por: Marks, Asher, et al.
Publicado: (2022)

NFB-04. Evaluating focal areas of signal intensity (FASI) in children with neurofibromatosis type-1 (NF1) treated with selumetinib on PBTC-029B
por: Pillay Smiley, Natasha, et al.
Publicado: (2022)

NFB-03. Neurological manifestations in children and adolescents with Neurofibromatosis type 1 - Implications for management and surveillance
por: Angelova-Toshkina, Daniela, et al.
Publicado: (2022)

NFB-09. Treatment of cardiac fibroma in aPTCH1-mutated Gorlin syndrome with medulloblastoma
por: Piccolo, Gianluca, et al.
Publicado: (2022)

NFB-06. Laser Interstitial Thermal Therapy as a Radiation-Sparing Approach for Children with Cancer Predisposition
por: Guadix, Sergio, et al.
Publicado: (2022)

NFB-01. Central nervous system tumors in Von Hippel-Lindau multisystem disorder: are there preventive approaches to escape tumor initiation at a young age?
por: Abdelmoula, Nouha Bouayed, et al.
Publicado: (2022)

NFB-08. TRAM-01: A Phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas
por: Kiaei, Dorsa Sadat, et al.
Publicado: (2022)

MODL-01. SAFETY IN CONCOMITANT USE OF MEK AND BRAF INHIBITORS WITH BEVACIZUMAB
por: Winzent, Shelby, et al.
Publicado: (2020)

QOL-36. USE OF CANNABINOIDS IN THE PEDIATRIC CENTRAL NERVOUS SYSTEM TUMOR POPULATION
por: Dorris, Kathleen, et al.
Publicado: (2020)

IMMU-20. EVALUATION OF CAR T CELLS IN EPENDYMOMA
por: Nellan, Anandani, et al.
Publicado: (2020)

LGG-27. TARGETED THERAPY FOR PEDIATRIC LOW-GRADE GLIOMAS AND PLEXIFORM NEUROFIBROMAS WITH TRAMETINIB
por: Nguyen, Tiffany, et al.
Publicado: (2020)

LGG-48. PROLIFIC GROWTH OF BRAF V600E MUTANT PILOCYTIC ASTROCYTOMA WHILE ON KETOGENIC DIET: CASE REPORT
por: Batchelder, Patti, et al.
Publicado: (2020)

Immunotherapy Associated Neurotoxicity in Pediatric Oncology
por: Shalabi, Haneen, et al.
Publicado: (2022)

Effect of early-stage autophagy inhibition in BRAF(V600E) autophagy-dependent brain tumor cells
por: Zahedi, Shadi, et al.
Publicado: (2019)

DDEL-06. DRUG INTERACTION BETWEEN EVEROLIMUS AND CANNABIDIOL IN PEDIATRIC PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMAS: A SINGLE INSTITUTION EXPERIENCE
por: Sabus, Ashley, et al.
Publicado: (2020)

SWK-10. Survivorship: Education, Clinical Guidelines, and Transition to Adult Care
por: Hemenway, Molly, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7onivco67rof5d4nptstse5354